Articles tagged with Drug Targets
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Researchers create a technique using prime editing to quickly and easily screen cancer genes, revealing new information on p53 mutations. The method allows for the analysis of over 1,000 different mutations in the tumor suppressor gene p53, which are seen in more than half of all cancer patients.
A new study found that more than half of American Indian teens had high levels of cholesterol, with nearly two-thirds of young adults experiencing the same issue. The study suggests a need for early screening and treatment to prevent premature heart disease.
A new study published in npj Antimicrobials and Resistance found that pathogenic bacteria E. coli and A. baumannii employ shared and unique mechanisms to acquire resistance to antibiotics ciprofloxacin and GP6. The researchers developed a method to track the acquisition of drug resistance using whole genome sequencing, which revealed t...
Research from UCSF found COVID antigens lingering in blood up to 14 months and tissue samples for over two years after infection. The persistence of these fragments may drive long COVID symptoms and associated risks.
Research has shown that dulaglutide, a diabetes drug, can reduce depressive-like behaviors in mice. The study identified four major pathways involved and linked markers of depression to lipid metabolism and tryptophan metabolism. This new perspective may facilitate the use of dulaglutide as a potential therapeutic strategy for depression.
Researchers at the University of Cincinnati Cancer Center have identified a new protein called p47 that helps prevent breast cancer metastasis. The study found that lower p47 expression was correlated with higher breast cancer metastasis, and that increasing p47 function could potentially lead to new therapies.
Purdue researchers have successfully isolated and detected drug-metabolizing enzymes from extracellular vesicles, which could enable personalized medicine by monitoring individual responses to prescription drugs. The method may also aid in detecting signs of Parkinson's disease and analyzing liver metabolism.
A recent study by Flinders University found that parents are conflicted and concerned about zero-alcohol drinks due to their similarity in taste and appearance. The research suggests that providing these drinks to adolescents may normalize alcohol consumption, leading to increased risks of harm.
The tumor microenvironment (TME) is a complex ecosystem surrounding tumors that impacts tumor development, metastasis, and responses to therapies. The review highlights potential therapeutic targets modulating TME components, including immune cells, stromal cells, and ECM proteins, to inhibit tumor progression.
A new study found that frequent cannabis use is associated with a higher risk of heart attack and stroke, even after controlling for tobacco use and other cardiovascular risk factors. The study analyzed data from over 430,000 adults in the US and found that smoking cannabis was significantly linked to cardiovascular risks.
The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
A novel chemotherapy approach uses patient's own cells as Trojan horses to deliver targeted cancer-killing drugs to lung cancer cells. The method has shown promise in reducing tumor size and improving treatment efficacy with minimal collateral damage to healthy tissues.
A new strategy used by cancer cells to protect themselves from immune system attack has been identified, and a potential target for immunotherapy has been found. Blocking activin receptor 1C on CD4+ T cells may help prevent the accumulation of immune-suppressing Tregs in tumors and slow tumor growth.
A team of researchers from the University of Tokyo demonstrated that a drug, valemetostat, reduces tumor growth in blood cancer by targeting H3K27me3, a protein modification silencing tumor suppressor genes. The treatment restores expression of many tumor suppressor genes and sustains inhibiting tumor cell growth.
Research discovers key contributors to skin tightening in systemic sclerosis, including myofibroblasts and endothelial cells. Targeting the Hippo signaling pathway shows promise for reversing fibrosis.
A new study suggests that Mark Cuban Cost Plus Drug Company (MCCPDC) may offer significant savings for patients taking common urology medications, with the greatest potential to reduce costs being for solifenacin and oxybutynin. The online pharmacy's standardized pricing can reduce out-of-pocket costs by up to $20 per prescription.
Researchers at São Paulo State University developed a novel technique using lipid nanoparticles to administer lupeol, killing Leishmania protozoan parasites. The therapy eliminated parasites from organs in animal tests, reducing spleen and liver parasite numbers by 99.9% with minimal side effects.
Prescription opioids linked to increased risk of serious falls among adults, with older individuals most vulnerable. Targeted prevention efforts may be most effective within the first month after opioid initiation.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
A new study from Uppsala University found that people who have had herpes virus are twice as likely to develop dementia as those who have never been infected. The researchers studied 1,000 70-year-olds over 15 years and confirmed previous research on the potential link between herpes and dementia.
Researchers use bacteriophages to target and kill drug-resistant bacteria, with a patient experiencing complete resolution of infection after combination therapy. However, immune response may lead to recurrence, highlighting need for further clinical trials.
Researchers found that an imbalance of CD4+ T cells in the lungs can exacerbate tuberculosis, leading to increased disease severity and reduced survival rates. Removing a specific receptor that recognizes extracellular ATP can improve the response of these T cells and potentially lead to new therapeutic interventions.
A new study published in The Lancet Oncology demonstrates that the drug enobosarm has anti-tumour effects in oestrogen receptor positive breast cancer patients, providing a novel approach to treatment. The study showed that enobosarm was well tolerated with no significant impact on quality of life.
Researchers found that adding blood thinners to clot-busting medications for ischemic strokes did not improve physical function at 90 days post-stroke. The study, MOST, enrolled 514 patients and analyzed the effectiveness of two blood-thinning medications.
Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.
A new study published in the American Heart Association journal Hypertension found that tirzepatide significantly lowered systolic blood pressure levels in nearly 500 adults with obesity. The results suggest treating obesity with this weight loss medication may be an effective strategy for preventing or treating high blood pressure.
Researchers discovered a new role for Mfsd7c in exporting excessive choline from the brain. The study suggests that targeting this protein could lead to therapeutic interventions for Alzheimer's disease and other neurological disorders.
Researchers discovered that reducing cholesterol levels in mice with advanced atherosclerosis leads to a decrease in the number of smooth muscle-derived cells causing plaque growth, while preserving stabilizing cell types. This finding opens up new opportunities for targeted therapies.
Researchers at University of Virginia Health System developed a new approach to machine learning that identifies drugs minimizing harmful scarring after heart attacks. The tool predicts and explains drug effects for other diseases as well.
A new study found that people with drug-related cardiac arrests in the U.S. were more likely to be younger and have fewer coexisting health conditions compared to non-drug-related cardiac arrests, which was a surprising finding given the increasing number of overdose deaths.
Researchers found that SGLT2 inhibitors reduced kidney stone rates by 30% compared to GLP1 agonists and 25% compared to DPP4 inhibitors. The study included data from 716,406 adults with type 2 diabetes who took these medications.
A new American Heart Association scientific statement emphasizes the need for increased awareness of cerebral venous thrombosis (CVT) to facilitate prompt medical treatment. The statement updates guidelines for diagnosing and managing CVT, focusing on advancements in treatment approaches.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
Researchers found combining common immune-suppressing drugs with a complement inhibitor effectively managed the initial human immune response against transplanted pig kidneys. The regimen, which relies solely on already FDA-approved medications, showed remarkable success in Parsons model case series.
A new study found that propranolol, a medication for high blood pressure, can lower anxiety levels in individuals with autism spectrum disorder. The study involved 69 patients and showed significantly reduced anxiety levels compared to a placebo group.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
Researchers have effectively targeted three distinct groups of cholangiocarcinoma, a lethal disease caused by liver fluke parasite or herbal carcinogen exposure. Experimental models show that specific treatments targeting these pathways can slow cancer growth and improve prognosis for CCA patients
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Scientists at the Advanced Science Research Center used X-ray crystallography with elevated temperature and pressure to observe distinct shapes in a protein molecule. The study reveals how proteins change shape to bind metabolites or other proteins, offering insight into disease treatment and development of novel drugs.
Researchers identified RBM5 as a key regulator of HOXA9 expression in leukemia cells, revealing its dual function in DNA and RNA handling. Removing RBM5 from cells significantly reduced HOXA9 mRNA levels, suggesting its potential as a therapeutic target for acute myeloid leukemia treatment.
Researchers from Scripps Research have developed a small molecule that blocks the activity of SLC15A4, a protein linked to autoimmune diseases like lupus and Crohn's disease. The compound, FFF-21, successfully reduced inflammation in mouse models and isolated cells from people with lupus.
Research suggests that structural changes in upper motor neurons send a signal to immune cells, leading to toxic effects on neurons and reduced synaptic connections. Blocking inflammation with a semi-synthetic drug can restore synaptic connections and improve ALS symptoms.
A global study has identified over 200 genes linked to depression, including 50 new genetic loci and 205 novel genes. The research also suggests potential for drug repurposing and highlights the need for more diverse genetic datasets to develop effective treatments.
Researchers at Tokyo Medical and Dental University characterize myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) using multiomics approaches, revealing distinct molecular features. This work provides crucial details for accurate diagnoses and therapeutic decisions.
Researchers have discovered a brain circuit that mediates panic disorder, consisting of specialized neurons that send and receive the neuropeptide PACAP. Inhibiting PACAP signaling reduces panic symptoms, offering promising findings for future treatments.
Scientists have mapped neuroblastoma tumors at the cell level and discovered a brake on the immune system that can be blocked with existing immunotherapy. A new combination treatment targeting TIGIT and PD-L1 is being developed, showing promising results in lab experiments.
Researchers at Icahn School of Medicine at Mount Sinai developed a novel genetic priority score (GPS) to integrate various types of human genetic data for easy target prioritization. The tool identifies genes with high potential for clinical trial success, particularly those with demonstrated genetic support.
Researchers uncovered insights into TAAR1's mechanism of action, highlighting significant differences between human and rodent models. The study suggests species-specific differences in drug-receptor interactions, paving the way for improved medications targeting substance use disorders.
Researchers have developed a novel method to produce a selective anticancer precursor substance. The synthesis involves the reaction of metal-active oxygen species with nitrile, utilizing cost-effective metals at lower temperatures. This breakthrough opens up new possibilities in developing innovative drugs against cancer.
A clinical trial found that diosmin reduced swelling at the knee, calf, and thigh up to 14 days after TKA, with lower pain scores on movement. The study also showed improved outcomes for short-term complications and a trend toward decreased postoperative nausea and vomiting.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
Klick Applied Sciences unveils LOVENet, an AI framework that rapidly identifies new therapeutic indications for existing drugs. The algorithm integrates large language model and structured knowledge graph technology to offer a fresh perspective on new potential applications.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
A new study found that deaths from infective endocarditis decreased overall in the US, but rose sharply among people ages 25-44, likely linked to the opioid crisis. Researchers call for more investigation into the trends and recommend comprehensive care plans including substance use disorder screening and treatment.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.